AroCell AB (publ) announced that Cecilia Ahlin joins the management team as Chief Medical Officer. Cecilia will lead and develop AroCell's clinical strategy with focus on getting more clinical evidence for the use of TK1 as a biomarker in cancer treatment. Cecilia Ahlin has over 20 years of experience treating cancer patients and has a PhD in prognostic factors in breast cancer. She became a specialist in general oncology in 2003 and in gynecological oncology in 2011.